Cadrenal Therapeutics (CVKD) said Tuesday it has signed a collaboration agreement with Abbott (ABT) to support a trial of its tecarfarin anticoagulation and hemocompatibility with left ventricular assist devices.

Financial terms were not disclosed.

Under the terms of the agreement, Abbott will support Cadrenal on the planning and execution of the trial to evaluate the efficacy and safety of tecarfarin in patients with left ventricular assist devices.

Abbott will also share insights from recent trials and will support Cadrenal with trial design, site identification, trial awareness, and expertise.